Veteran Seattle biotech player Steven Quay wants to fund his diagnostic testing company, Atossa Genetics, through a $15 million IPO. No underwriters are signed on yet, though. Quay is the former CEO of Sonus and Nastech, explains Xconomy, neither of which have fared well. Report